Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Telavancin (Theravance).

John L Pace1, J Kevin Judice

  • 1LifeNet Inc, R&D Department, Virginia Beach, VA 23455, USA. jlpymp@yahoo.com

Current Opinion in Investigational Drugs (London, England : 2000)
|March 9, 2005
PubMed
Summary

Theravance is developing telavancin, a novel injectable antibiotic targeting Gram-positive bacterial infections. Phase III clinical trials are underway for complicated skin and skin structure infections.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Approved Glycopeptide Antibacterial Drugs: Mechanism of Action and Resistance.

Cold Spring Harbor perspectives in medicine·2016
Same author

A multivalent approach to drug discovery for novel antibiotics.

The Journal of antibiotics·2009
Same author

Exploring the positional attachment of glycopeptide/beta-lactam heterodimers.

The Journal of antibiotics·2009
Same author

Glycopeptides: Update on an old successful antibiotic class.

Biochemical pharmacology·2006
Same author

Prevention of disease in ferrets fed an inactivated whole cell Campylobacter jejuni vaccine.

Vaccine·2005
Same author

Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424).

The Journal of antibiotics·2004

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Clinical Trials

Background:

  • Gram-positive bacterial infections pose a significant therapeutic challenge.
  • Novel antibiotics are crucial for combating resistant bacterial strains.

Purpose of the Study:

  • To evaluate the efficacy and safety of telavancin.
  • To assess telavancin's potential in treating Gram-positive bacterial infections.

Main Methods:

  • Telavancin is an injectable peptidoglycan inhibitor antibiotic.
  • Phase III clinical trials initiated in September 2004.
  • Trials focus on complicated skin and skin structure infections.

Main Results:

  • Data from Phase III trials are pending.
  • Efficacy and safety profiles are under investigation.

Conclusions:

  • Telavancin shows promise as a treatment for Gram-positive bacterial infections.
  • Further results from ongoing trials will determine its clinical utility.

Related Experiment Videos